-
2023-504989-37-00
5
Metastatic Squamous Non-small Cell Lung Cancer
-
2024-519087-41-00
5
Breast cancer is the most common form of cancer among women in North A
-
2025-520622-38-00
5
Urinary Tract Infections
-
2025-521221-32-00
5
Advanced or Metastatic Non-Small Cell Lung Cancer
-
2025-522255-25-00
5
2026-05-18
Fallopian Tube Neoplasms
-
2025-521884-12-00
5
2026-03-19
First line triple-negative breast cancer (TNBC)
-
2022-501606-35-01
11
2024-02-21
Platinum-sensitive epithelial ovarian, fallopian tube, or primary
peri
-
2024-516066-11-00
5
2022-08-31
Patients with newly diagnosed, histologically confirmed, primary advan
-
2024-518223-29-00
4
2020-03-10
Advanced or metastatic untreated EGFR mutation positive NSCLC
-
2024-515765-34-00
5
2026-02-04
English
First-line extensive-stage small-cell lung cancer (ES-SCLC)
-
2024-517780-24-00
5
2025-09-18
Lung Cancer
-
2024-515884-69-00
5
2025-07-16
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
-
2024-515764-31-00
10
2025-06-13
Non-small cell lung cancer
-
2024-511945-20-00
4
2025-01-24
patients affected by small cell lung cancer (SCLC)
-
2023-509340-10-00
5
2024-10-29
Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
-
2023-506632-32-00
5
2024-10-28
Metastatic colorectal cancer
-
2024-513087-26-00
5
2024-09-10
Metastatic Non-small Cell Lung Cancer
-
2023-508359-38-00
5
2024-06-05
Early-stage Non-squamous Non-small Cell Lung Cancer
-
2023-505928-59-00
5
2024-04-15
Triple Negative or Hormone Receptor low/HER2-negative Breast Cancer
-
2022-500802-16-00
5
2023-11-01
Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung
-
2023-504194-21-00
5
2022-09-13
PD-L1 Positive Metastatic Triple-Negative Breast Cancer
-
2023-507964-38-00
5
2022-09-01
Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutate
-
2023-504195-14-00
5
2022-08-31
PD-L1-negative metastatic triple-negative breast cancer or PD-L1-posit
-
2023-507933-12-00
5
2022-08-18
Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)